268 related articles for article (PubMed ID: 17709754)
1. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo.
Purcell NH; Wilkins BJ; York A; Saba-El-Leil MK; Meloche S; Robbins J; Molkentin JD
Proc Natl Acad Sci U S A; 2007 Aug; 104(35):14074-9. PubMed ID: 17709754
[TBL] [Abstract][Full Text] [Related]
2. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy.
Kehat I; Molkentin JD
Ann N Y Acad Sci; 2010 Feb; 1188():96-102. PubMed ID: 20201891
[TBL] [Abstract][Full Text] [Related]
3. DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.
Maillet M; Purcell NH; Sargent MA; York AJ; Bueno OF; Molkentin JD
J Biol Chem; 2008 Nov; 283(45):31246-55. PubMed ID: 18753132
[TBL] [Abstract][Full Text] [Related]
4. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth.
Kehat I; Davis J; Tiburcy M; Accornero F; Saba-El-Leil MK; Maillet M; York AJ; Lorenz JN; Zimmermann WH; Meloche S; Molkentin JD
Circ Res; 2011 Jan; 108(2):176-83. PubMed ID: 21127295
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
[TBL] [Abstract][Full Text] [Related]
6. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice.
Bueno OF; De Windt LJ; Tymitz KM; Witt SA; Kimball TR; Klevitsky R; Hewett TE; Jones SP; Lefer DJ; Peng CF; Kitsis RN; Molkentin JD
EMBO J; 2000 Dec; 19(23):6341-50. PubMed ID: 11101507
[TBL] [Abstract][Full Text] [Related]
7. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
[TBL] [Abstract][Full Text] [Related]
8. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo.
Lips DJ; Bueno OF; Wilkins BJ; Purcell NH; Kaiser RA; Lorenz JN; Voisin L; Saba-El-Leil MK; Meloche S; Pouysségur J; Pagès G; De Windt LJ; Doevendans PA; Molkentin JD
Circulation; 2004 Apr; 109(16):1938-41. PubMed ID: 15096454
[TBL] [Abstract][Full Text] [Related]
9. Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction.
Ulm S; Liu W; Zi M; Tsui H; Chowdhury SK; Endo S; Satoh Y; Prehar S; Wang R; Cartwright EJ; Wang X
J Mol Cell Cardiol; 2014 Jul; 72(100):104-16. PubMed ID: 24631771
[TBL] [Abstract][Full Text] [Related]
10. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death.
Bueno OF; Molkentin JD
Circ Res; 2002 Nov; 91(9):776-81. PubMed ID: 12411391
[TBL] [Abstract][Full Text] [Related]
11. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation.
Marchetti S; Gimond C; Chambard JC; Touboul T; Roux D; Pouysségur J; Pagès G
Mol Cell Biol; 2005 Jan; 25(2):854-64. PubMed ID: 15632084
[TBL] [Abstract][Full Text] [Related]
12. IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload.
Sbroggiò M; Carnevale D; Bertero A; Cifelli G; De Blasio E; Mascio G; Hirsch E; Bahou WF; Turco E; Silengo L; Brancaccio M; Lembo G; Tarone G
Cardiovasc Res; 2011 Aug; 91(3):456-64. PubMed ID: 21493702
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases.
Warnecke C; Kaup D; Marienfeld U; Poller W; Yankah C; Gräfe M; Fleck E; Regitz-Zagrosek V
J Mol Med (Berl); 2001 Sep; 79(9):510-21. PubMed ID: 11692164
[TBL] [Abstract][Full Text] [Related]
14. Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction.
Zhang Y; Zhang XF; Gao L; Liu Y; Jiang DS; Chen K; Yang Q; Fan GC; Zhang XD; Huang C
Biochim Biophys Acta; 2014 Feb; 1842(2):232-44. PubMed ID: 24275554
[TBL] [Abstract][Full Text] [Related]
15. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Li CY; Zhou Q; Yang LC; Chen YH; Hou JW; Guo K; Wang YP; Li YG
Basic Res Cardiol; 2016 Mar; 111(2):19. PubMed ID: 26891723
[TBL] [Abstract][Full Text] [Related]
16. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.
Bueno OF; De Windt LJ; Lim HW; Tymitz KM; Witt SA; Kimball TR; Molkentin JD
Circ Res; 2001 Jan; 88(1):88-96. PubMed ID: 11139479
[TBL] [Abstract][Full Text] [Related]
17. Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.
Ruppert C; Deiss K; Herrmann S; Vidal M; Oezkur M; Gorski A; Weidemann F; Lohse MJ; Lorenz K
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7440-5. PubMed ID: 23589880
[TBL] [Abstract][Full Text] [Related]
18. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.
Lorenz K; Schmitt JP; Schmitteckert EM; Lohse MJ
Nat Med; 2009 Jan; 15(1):75-83. PubMed ID: 19060905
[TBL] [Abstract][Full Text] [Related]
19. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.
Oudit GY; Kassiri Z; Zhou J; Liu QC; Liu PP; Backx PH; Dawood F; Crackower MA; Scholey JW; Penninger JM
Cardiovasc Res; 2008 Jun; 78(3):505-14. PubMed ID: 18281373
[TBL] [Abstract][Full Text] [Related]
20. Phosphatase-mediated crosstalk control of ERK and p38 MAPK signaling in corneal epithelial cells.
Wang Z; Yang H; Tachado SD; Capó-Aponte JE; Bildin VN; Koziel H; Reinach PS
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5267-75. PubMed ID: 17122112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
